Clinical trial
A second-line, single arm, phase II clinical study with tremelimumab, a fully humanized anti-CTLA-4 monoclonal antibody, as monotherapy in patients with unresectable malignant mesothelioma
To assess the rate of objective clinical complete response (CR) or partial response (PR)
| Category | Value |
|---|---|
| Study start date | 2012-08-03 |